244 related articles for article (PubMed ID: 30462853)
41. Constitutive lymphocyte transmigration across the basal lamina of high endothelial venules is regulated by the autotaxin/lysophosphatidic acid axis.
Bai Z; Cai L; Umemoto E; Takeda A; Tohya K; Komai Y; Veeraveedu PT; Hata E; Sugiura Y; Kubo A; Suematsu M; Hayasaka H; Okudaira S; Aoki J; Tanaka T; Albers HM; Ovaa H; Miyasaka M
J Immunol; 2013 Mar; 190(5):2036-48. PubMed ID: 23365076
[TBL] [Abstract][Full Text] [Related]
42. Targeting the hydrophobic pocket of autotaxin with virtual screening of inhibitors identifies a common aromatic sulfonamide structural motif.
Fells JI; Lee SC; Norman DD; Tsukahara R; Kirby JR; Nelson S; Seibel W; Papoian R; Patil R; Miller DD; Parrill AL; Pham TC; Baker DL; Bittman R; Tigyi G
FEBS J; 2014 Feb; 281(4):1017-28. PubMed ID: 24314137
[TBL] [Abstract][Full Text] [Related]
43. Biological roles of lysophosphatidic acid signaling through its production by autotaxin.
Okudaira S; Yukiura H; Aoki J
Biochimie; 2010 Jun; 92(6):698-706. PubMed ID: 20417246
[TBL] [Abstract][Full Text] [Related]
44. Discovery and optimization of boronic acid based inhibitors of autotaxin.
Albers HM; van Meeteren LA; Egan DA; van Tilburg EW; Moolenaar WH; Ovaa H
J Med Chem; 2010 Jul; 53(13):4958-67. PubMed ID: 20536182
[TBL] [Abstract][Full Text] [Related]
45. Optimization of a pipemidic acid autotaxin inhibitor.
Hoeglund AB; Bostic HE; Howard AL; Wanjala IW; Best MD; Baker DL; Parrill AL
J Med Chem; 2010 Feb; 53(3):1056-66. PubMed ID: 20041668
[TBL] [Abstract][Full Text] [Related]
46. An Autotaxin/Lysophosphatidic Acid/Interleukin-6 Amplification Loop Drives Scleroderma Fibrosis.
Castelino FV; Bain G; Pace VA; Black KE; George L; Probst CK; Goulet L; Lafyatis R; Tager AM
Arthritis Rheumatol; 2016 Dec; 68(12):2964-2974. PubMed ID: 27390295
[TBL] [Abstract][Full Text] [Related]
47. Design, synthesis, docking and biological evaluation of 4-phenyl-thiazole derivatives as autotaxin (ATX) inhibitors.
Balupuri A; Lee DY; Lee MH; Chae S; Jung E; Kim Y; Ryu J; Kang NS
Bioorg Med Chem Lett; 2017 Sep; 27(17):4156-4164. PubMed ID: 28743508
[TBL] [Abstract][Full Text] [Related]
48. Pharmacologic targeting of the ATX/LPA axis attenuates bleomycin-induced pulmonary fibrosis.
Ninou I; Kaffe E; Müller S; Budd DC; Stevenson CS; Ullmer C; Aidinis V
Pulm Pharmacol Ther; 2018 Oct; 52():32-40. PubMed ID: 30201409
[TBL] [Abstract][Full Text] [Related]
49. Discovery of potent chromone-based autotaxin inhibitors inspired by cannabinoids.
Eymery MC; Nguyen KA; Basu S; Hausmann J; Tran-Nguyen VK; Seidel HP; Gutierrez L; Boumendjel A; McCarthy AA
Eur J Med Chem; 2024 Jan; 263():115944. PubMed ID: 37976710
[TBL] [Abstract][Full Text] [Related]
50. The Bulk of Autotaxin Activity Is Dispensable for Adult Mouse Life.
Katsifa A; Kaffe E; Nikolaidou-Katsaridou N; Economides AN; Newbigging S; McKerlie C; Aidinis V
PLoS One; 2015; 10(11):e0143083. PubMed ID: 26569406
[TBL] [Abstract][Full Text] [Related]
51. Hits of a high-throughput screen identify the hydrophobic pocket of autotaxin/lysophospholipase D as an inhibitory surface.
Fells JI; Lee SC; Fujiwara Y; Norman DD; Lim KG; Tsukahara R; Liu J; Patil R; Miller DD; Kirby RJ; Nelson S; Seibel W; Papoian R; Parrill AL; Baker DL; Bittman R; Tigyi G
Mol Pharmacol; 2013 Sep; 84(3):415-24. PubMed ID: 23793291
[TBL] [Abstract][Full Text] [Related]
52. Non-invasive imaging of tumors by monitoring autotaxin activity using an enzyme-activated near-infrared fluorogenic substrate.
Madan D; Ferguson CG; Lee WY; Prestwich GD; Testa CA
PLoS One; 2013; 8(11):e79065. PubMed ID: 24278115
[TBL] [Abstract][Full Text] [Related]
53. The autotaxin-lysophosphatidic acid-lysophosphatidic acid receptor cascade: proposal of a novel potential therapeutic target for treating glioblastoma multiforme.
Tabuchi S
Lipids Health Dis; 2015 Jun; 14():56. PubMed ID: 26084470
[TBL] [Abstract][Full Text] [Related]
54. Lysoglycerophospholipids in chronic inflammatory disorders: the PLA(2)/LPC and ATX/LPA axes.
Sevastou I; Kaffe E; Mouratis MA; Aidinis V
Biochim Biophys Acta; 2013 Jan; 1831(1):42-60. PubMed ID: 22867755
[TBL] [Abstract][Full Text] [Related]
55. The role and therapeutic potential of the autotaxin-lysophosphatidate signalling axis in breast cancer.
Teo K; Brunton VG
Biochem J; 2014 Oct; 463(1):157-65. PubMed ID: 25195735
[TBL] [Abstract][Full Text] [Related]
56. [Clinical introduction of lysophosphatidic acid and autotaxin assays].
Yatomi Y
Rinsho Byori; 2010 Jun; 58(6):631-5. PubMed ID: 20662276
[TBL] [Abstract][Full Text] [Related]
57. Autotaxin is expressed in FLT3-ITD positive acute myeloid leukemia and hematopoietic stem cells and promotes cell migration and proliferation.
Ortlepp C; Steudel C; Heiderich C; Koch S; Jacobi A; Ryser M; Brenner S; Bornhäuser M; Brors B; Hofmann WK; Ehninger G; Thiede C
Exp Hematol; 2013 May; 41(5):444-461.e4. PubMed ID: 23377000
[TBL] [Abstract][Full Text] [Related]
58. Identification of two novel chemical classes of Autotaxin (ATX) inhibitors using Enalos Asclepios KNIME nodes.
Stylianaki EA; Mouchlis VD; Magkrioti C; Papavasileiou KD; Afantitis A; Matralis AN; Aidinis V
Bioorg Med Chem Lett; 2024 May; 103():129690. PubMed ID: 38447786
[TBL] [Abstract][Full Text] [Related]
59. Autotaxin inhibition: development and application of computational tools to identify site-selective lead compounds.
Norman DD; Ibezim A; Scott WE; White S; Parrill AL; Baker DL
Bioorg Med Chem; 2013 Sep; 21(17):5548-60. PubMed ID: 23816044
[TBL] [Abstract][Full Text] [Related]
60. Both plasma lysophosphatidic acid and serum autotaxin levels are increased in chronic hepatitis C.
Watanabe N; Ikeda H; Nakamura K; Ohkawa R; Kume Y; Aoki J; Hama K; Okudaira S; Tanaka M; Tomiya T; Yanase M; Tejima K; Nishikawa T; Arai M; Arai H; Omata M; Fujiwara K; Yatomi Y
J Clin Gastroenterol; 2007 Jul; 41(6):616-23. PubMed ID: 17577119
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]